WE downgrade the stock to "sell" as: (1) Singapore's growth missed again for the third straight quarter and underlying weakness is structural in our view; (2) management guided for...

SINGAPORE-LISTED Raffles Medical Group achieved a one per cent year-on-year growth in second-quarter revenue to S$120.1 million despite softer-than-expected demand from foreign patients.